Peking University is conducting a single center study looking at the impact of Teriflunomide on adults between 18-80 years who have steroid-resistant or returning ITP. Teriflunomide is an immune modulator that is believed to decrease inflammation and the action of immune cells in ITP. Eligible participants must have a platelet count less than 30,000 or less than 50,000 with bleeding symptoms requiring treatment. Investigators are hoping to enroll forty primary ITP patients who meet study criteria.
China
Actively Recruiting